Idexx Laboratories Inc /De reports $4.3 billion revenue for fiscal year ended December 31, 2025, up 10.4%
Idexx Laboratories Inc /De reported revenue of $4.3 billion for the year ended December 31, 2025, an increase of 10.4% from the previous year ($3.9 billion).
For the same period it posted net income of $1.06 billion, up 19.3%, or $13.08 per diluted share (10.67 a year earlier).
That is a net margin of 24.6%.
On Sanad's AAOIFI Standard 21 screen, Idexx Laboratories Inc /De is currently compliant: interest-bearing debt is 0.7% of market capitalisation (limit 30%), and impure income is 0.1% of revenue (limit 5%).
Is Idexx Laboratories Inc /De halal?
See the full AAOIFI screening of Idexx Laboratories Inc /De
See the full AAOIFI screening of Idexx Laboratories Inc /De
Source: 10-K filed with the U.S. Securities and Exchange Commission on February 20, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.